임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

19건 표시

3상모집 중단 (진행 중)· Respiratory Syncytial Virus Infections
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
리드: GSK
상세 →NCT06534892
3상모집 중단 (진행 중)· Glioblastoma
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
협력: GSK
상세 →NCT06388733
3상모집 중단 (진행 중)· Lung Cancer, Non-Small Cell
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
리드: GSK
상세 →NCT06472076
3상모집 중단 (진행 중)· Herpes Zoster
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
리드: GSK
상세 →NCT05371080
3상모집 중단 (진행 중)· Asthma
Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma
협력: GSK
상세 →NCT04651777
3상모집 중단 (진행 중)· Eosinophilic Granulomatosis With Polyangiitis
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
리드: GSK
상세 →NCT05263934
3상모집 중단 (진행 중)· Endometrial Cancer
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
협력: GSK
상세 →NCT05201547
3상모집 중단 (진행 중)· Multiple Myeloma
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
리드: GSK
상세 →NCT06956170
3상모집 중단 (진행 중)· Multiple Myeloma
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
리드: GSK
상세 →NCT06868654
3상모집 중단 (진행 중)· Multiple Myeloma
Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
리드: GSK
상세 →NCT06868667
3상모집 중단 (진행 중)· Neoplasms, Breast
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
리드: GSK
상세 →NCT04915755
3상모집 중단 (진행 중)· Respiratory Syncytial Virus Infections
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
리드: GSK
상세 →NCT04732871
3상모집 중단 (진행 중)· Multiple Myeloma
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
리드: GSK
상세 →NCT04484623
3상모집 중단 (진행 중)· Cholestasis
Linerixibat Long-term Safety, and Tolerability Study
리드: GSK
상세 →NCT04167358
3상모집 중단 (진행 중)· Multiple Myeloma
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
리드: GSK
상세 →NCT04246047
3상모집 중단 (진행 중)· Multiple Myeloma
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
리드: GSK
상세 →NCT04162210
3상모집 중단 (진행 중)· Lupus Erythematosus, Systemic
Synergetic B-cell Immunomodulation in SLE - 2nd Study.
협력: GSK
상세 →NCT03747159
3상모집 중단 (진행 중)· Infection, Human Immunodeficiency Virus
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
협력: GSK
상세 →NCT02951052
3상모집 중단 (진행 중)· HIV Infections
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
협력: GSK
상세 →NCT02938520

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.